Literature DB >> 20919414

Pharmacokinetic and clinical studies on cefuroxime.

R Norrby, R D Foord, J D Price, P Hedlund.   

Abstract

Entities:  

Year:  1977        PMID: 20919414      PMCID: PMC1543257     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  9 in total

1.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  Clinical and pharmacokinetic studies on cefuroxime.

Authors:  R Norrby; R D Foord; P Hedlund
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

3.  Development of meningitis during cephalothin therapy.

Authors:  R J Mangi; R S Kundargi; R Quintiliani; V T Andriole
Journal:  Ann Intern Med       Date:  1973-03       Impact factor: 25.391

4.  Meningococcal infection unresponsive to cephalothin.

Authors:  H R Almond
Journal:  N Engl J Med       Date:  1969-07-24       Impact factor: 91.245

5.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

6.  Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine.

Authors:  R Norrby; J E Brorsson; S Seeberg
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

8.  Positive direct Coombs tests due to cephalothin.

Authors:  L Molthan; M M Reidenberg; M F Eichman
Journal:  N Engl J Med       Date:  1967-07-20       Impact factor: 91.245

9.  Comparative study of seven cephalosporins: susceptibility to beta-lactamases and ability to penetrate the surface layers of Escherichia coli.

Authors:  M H Richmond; S Wotton
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

  9 in total
  9 in total

1.  A survey of the sensitivity of fresh clinical isolates to cefuroxime and other antibiotics.

Authors:  L O Potaschmacher; C H Dash; K A Jefferson; M R Kennedy
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

2.  Fluorimetric determination of cefuroxime in body fluids.

Authors:  Z H Al-Rawi; S Tabaqchali
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

Review 3.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

Review 4.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics.

Authors:  S R Norrby
Journal:  Med Toxicol       Date:  1986 Jan-Feb

6.  An adenosine triphosphate-dependent carbamoylphosphate--3-hydroxymethylcephem O-carbamoyltransferase from Streptomyces clavuligerus.

Authors:  S J Brewer; P M Taylor; M K Turner
Journal:  Biochem J       Date:  1980-03-01       Impact factor: 3.857

7.  Comparison of cefuroxime and penicillin in the treatment of uncomplicated gonorrhea.

Authors:  J G Lossick; S E Thompson; M P Smeltzer
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

8.  Cefuroxime in bacterial meningitis.

Authors:  J Pfenninger; U B Schaad; J Lütschg; A Nussbaumer; U Zellweger
Journal:  Arch Dis Child       Date:  1982-07       Impact factor: 3.791

9.  Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency.

Authors:  R A Walstad; O G Nilsen; K J Berg
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.